42 research outputs found
Social Change and Women's Reproductive Health Care: A Guide for Physicians and Their Patients. Nada Logan Stotland.
El movimiento de mujeres en Canadá: una historia de dos culturas eurocéntricas y tres naciones
Nurses\u27 Alumnae Association Bulletin - Volume 2 Number 1
March of Activities
Treasurer\u27s Report
It\u27s a Date
Loyalty
Coming Events
Jefferson News
In Florida for Winter
The A.N.A. Convention
Greetings!
Keeping Up the Fight
Eight Hour Committee
Nurses Wanted
Class of 1926
Convention Notes
Attention Members
Pine Street News
Class of 1915
Class of 1916
Fifth Anniversary
Prize Winners - 1932
Class of 1940
Owners of Scrap Books
Sick List - 1939 and 1940
A Program of Nursing Information Please
Private Duty Section
Excerpts from Alumnae Minutes
Staff News
Please Remember
Personals
Engagements
Marriages
Deaths
Hospital News
Ballot for Officers
Recent Births
Lest You Forget!
Please Change My Addres
Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia
The leukemogenic effects of Myc drive recurrent trisomy in a mouse model of acute myeloid leukemia
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial
Background
From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, and ravulizumab, a monoclonal inhibitor of complement C5 activation, as an adjunct to standard of care for the treatment of adult patients hospitalised with COVID-19.
Methods
TACTIC-R was a phase 4, randomised, parallel-arm, open-label platform trial that was undertaken in the UK with urgent public health designation to assess the potential of repurposing immunosuppressants for the treatment of severe COVID-19, stratified by a risk score. Adult participants (aged ≥18 years) were enrolled from 22 hospitals across the UK. Patients with a risk score indicating a 40% risk of admission to an intensive care unit or death were randomly assigned 1:1:1 to standard of care alone, standard of care with baricitinib, or standard of care with ravulizumab. The composite primary outcome was the time from randomisation to incidence (up to and including day 14) of the first event of death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure. The primary interim analysis was triggered when 125 patient datasets were available up to day 14 in each study group and we included in the analysis all participants who were randomly assigned. The trial was registered on ClinicalTrials.gov (NCT04390464).
Findings
Between May 8, 2020, and May 7, 2021, 417 participants were recruited and randomly assigned to standard of care alone (145 patients), baricitinib (137 patients), or ravulizumab (135 patients). Only 54 (39%) of 137 patients in the baricitinib group received the maximum 14-day course, whereas 132 (98%) of 135 patients in the ravulizumab group received the intended dose. The trial was stopped after the primary interim analysis on grounds of futility. The estimated hazard ratio (HR) for reaching the composite primary endpoint was 1·11 (95% CI 0·62–1·99) for patients on baricitinib compared with standard of care alone, and 1·53 (0·88–2·67) for ravulizumab compared with standard of care alone. 45 serious adverse events (21 deaths) were reported in the standard-of-care group, 57 (24 deaths) in the baricitinib group, and 60 (18 deaths) in the ravulizumab group.
Interpretation
Neither baricitinib nor ravulizumab, as administered in this study, was effective in reducing disease severity in patients selected for severe COVID-19. Safety was similar between treatments and standard of care. The short period of dosing with baricitinib might explain the discrepancy between our findings and those of other trials. The therapeutic potential of targeting complement C5 activation product C5a, rather than the cleavage of C5, warrants further evaluation